Shopping Cart

Your shopping cart is currently empty

Vitamin D3

Name: Vitamin D3
Brand: TargetMol
SKU: T1135
Price: 33 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: Colecalciferol, Cholecalciferol) Copy Product Info

😃Good

Synonyms: Colecalciferol, Cholecalciferol

Catalog No. T1135 Copy Product Info

Purity: 99.93%

😃Good

Vitamin D3 (cholecalciferol) is a naturally occurring form of vitamin D; once metabolically activated, it can induce cellular differentiation and cancer cell proliferation. Vitamin D3 can be used to establish kidney stone models and is also an important research target in the fields of immunology and oncology.

Cas No. 67-97-0

Pack Size	Price	USA Stock	Global Stock	Quantity
1 g	$33	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$39	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.93%

Color:White to Yellow

Resource Download

COA HNMR HPLC

Product Introduction

Vitamin D3 AI Summary

Vitamin D3 exhibits a broad range of bioactivities involving various cellular and molecular mechanisms. It plays a significant role in the transformation of vitamin D to previtamin D, displaying kinetic parameters such as a kinetic constant (Keq) of 3.71, a forward reaction rate constant (k1) of 50400.0 s⁻¹, and a reverse reaction rate constant (k-1) of 13600.0 s⁻¹. It shows competitive inhibition against [3H]25-(OH)-D3 for binding with rat plasma Vitamin D binding protein, with a B50 value of 3.38E-7 M, indicating its potential interaction with the Vitamin D binding protein. The compound exhibits significant bioactivity in various cell assays, such as upregulating CYP24A1 mRNA expression in different cell lines, demonstrating competitive binding affinity to full-length human VDR, and showing activation with an EC50 of 0.21 nM in a luciferase reporter gene assay in HEK293 cells. Furthermore, Vitamin D3 inhibits the Hedgehog signaling pathway, evidenced by reductions in Gli1 mRNA expression in various cell lines, with IC50 values ranging from 2100.0 nM to 13600.0 nM. Vitamin D3 is also involved in enzyme inhibition, showing activity against enzymes like rhodanese and malate dehydrogenase (MDH), and demonstrating selectivity towards E. coli GroEL/GroES proteins. Additionally, it has antiviral properties, notably inhibiting SARS-CoV-2-induced cytotoxicity in various cell assays and acting as a SARS-CoV-2 3CL-Pro protease inhibitor with an inhibition percentage of 14.36% at 20µM. The compound influences multiple physiological functions, impacting liver and kidney function markers, electrolyte levels, and blood cell parameters. It enhances the metabolic activity of cells, affects cell viability, and has been shown to posses both estrogen agonistic and antagonistic activity. Moreover, it demonstrates ROS scavenging activity in HUVEC cells under high glucose conditions. Overall, Vitamin D3 exhibits significant biological activities related to vitamin D receptor activation, hedgehog signaling inhibition, enzyme inhibition, and antiviral properties, making it a potent and versatile compound in biomedical research..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Vitamin D3 (cholecalciferol) is a naturally occurring form of vitamin D; once metabolically activated, it can induce cellular differentiation and cancer cell proliferation. Vitamin D3 can be used to establish kidney stone models and is also an important research target in the fields of immunology and oncology.
Targets & IC50	H305F/H397Y mutant vitamin D receptor:300 nM(Kd)
In vitro	Methods: IK, RL95/2, and HEC1-A cells were treated with 2–10 μM vitamin D3 for 24, 48, or 72 hours, and cell viability was assessed using the MTT assay. Results: Vitamin D3 inhibited cell viability in a dose- and time-dependent manner, with the strongest inhibitory effect observed after 72 hours of treatment with 10 μM vitamin D3.[1] Methods: IK cells were treated with 10 μM vitamin D3 for 0–48 h. Intracellular 25(OH)D levels were measured using chemiluminescence, and VDR nuclear translocation was assessed by immunofluorescence and Western blot. Results: Vitamin D3 treatment for 48 h was required to detect 25(OH)D production, accompanied by VDR nuclear translocation.[1]
In vivo	Methods: Male ddY mice were divided into 4 groups (solvent control, Vitamin D3 alone, CCl₄ alone, Vitamin D3 + CCl₄). Mice were pretreated with Vitamin D3 (5 mg/kg) administered via gavage for 4 consecutive days, followed by intraperitoneal injection of CCl₄ (2 g/kg) on Day 0. A separate group received a direct injection of CaCl₂ (150 mg/kg) to validate the role of calcium. Results: Vitamin D3 alone significantly increased serum calcium levels to 13.0 mg/dL (normal: 7.77 mg/dL), with no evidence of liver or kidney damage or oxidative stress.[2]
Synonyms	Colecalciferol, Cholecalciferol
Disease Modeling Protocol	Kidney stone model Modeling Mechanism： Vitamin D3 enhances intestinal calcium absorption through the VDR (vitamin D receptor) signaling pathway, leading to hypercalciuria; the combined use of calcium and vitamin D produces a synergistic effect, promoting the deposition of calcium phosphate in the kidneys and the formation of stones. Related Products： Vitamin D3 (T1135) Modeling Method： Experimental Subject： Rats: Sprague-Dawley, male, 38 weeks old Dosage and Administration Route： 1. Vitamin D group: 100,000 IU/kg, intramuscular injection, once every 3 weeks 2. Calcium group: 2 g/L calcium gluconate solution, ad libitum 3. Combined group: Vitamin D regimen above+calcium drinking water regimen above Baseline conditions: Standard diet (containing 600 IU vitamin D3/kg, 0.73% calcium); control group provided with standard drinking water containing 80 mg/L calcium Dosing Frequency and Duration Model： Every 3 weeks Validation： 1. Urinary indicators: Urinary calcium excretion increased significantly from week 8, and calcium oxalate and calcium phosphate crystals were visible under microscopy; 2. Imaging indicators: Quantitative micro-CT showed that the average calcified volume of the kidneys in the combined group reached 0.121 mm³; 3. Pathological indicators: von Kossa/Yasue staining confirmed the presence of calcification and stone deposition in the renal tubules; 4. Composition identification: Infrared spectroscopy confirmed that the stones were carbonate apatite and amorphous calcium phosphate, and scanning electron microscopy showed typical stone crystal structures. Precautions： Calcium or vitamin D alone cannot form significant stones; they must be used in combination. References：Letavernier E,et,al. Calcium and vitamin D have a synergistic role in a rat model of kidney stone disease. Kidney Int. 2016 Oct;90(4):809-17.

Chemical Properties

Molecular Weight	384.64
Formula	C₂₇H₄₄O
Cas No.	67-97-0
Smiles	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Relative Density.	0.96 g/cm3

Storage & Solubility Information

Storage

Keep away from direct sunlight,The compound is unstable in solution. Please use soon Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 252.5 mg/mL (656.46 mM), Sonication is recommended. (The compound is unstable in solution, please use soon.)

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.6 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5998 mL	12.9992 mL	25.9983 mL	129.9917 mL
5 mM	0.5200 mL	2.5998 mL	5.1997 mL	25.9983 mL
10 mM	0.2600 mL	1.2999 mL	2.5998 mL	12.9992 mL
20 mM	0.1300 mL	0.6500 mL	1.2999 mL	6.4996 mL
50 mM	0.0520 mL	0.2600 mL	0.5200 mL	2.5998 mL
100 mM	0.0260 mL	0.1300 mL	0.2600 mL	1.2999 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc